Draft:AB-MDMSBA

{{AFC submission|d|exists|AB-MDMSBA|u=BCanalyst|ns=118|decliner=Fade258|declinets=20250613144918|ts=20250612233350}}

{{AFC submission|d|nn|u=BCanalyst|ns=118|decliner=DoubleGrazing|declinets=20250609073307|small=yes|ts=20250609072659}}

{{AFC comment|1=There is already an article on this topic. Fade258 (talk) 14:49, 13 June 2025 (UTC)}}

{{AFC comment|1=In accordance with Wikipedia's Conflict of interest policy, I disclose that I have a conflict of interest regarding the subject of this article. BCanalyst (talk) 07:25, 9 June 2025 (UTC)}}

----

{{Short description|Designer drug }}

{{Draft topics|chemistry|medicine-and-health}}

{{AfC topic|other}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| INN =

| type =

| image = AB-MDMSBA.tif

| width =

| alt =

| caption =

| image2 =

| width2 =

| alt2 =

| caption2 =

| imageL =

| widthL =

| altL =

| imageR =

| widthR =

| altR =

| captionLR =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem = 172872001

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name = N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-3-(dimethylsulfamoyl)-4-methylbenzamide

| C = 15

| H = 23

| N = 3

| O = 4

| S = 1

| molecular_weight =

| SMILES = CC1=C(C=C(C=C1)C(=O)N[C@@H](C(C)C)C(=O)N)S(=O)(=O)N(C)C

| Jmol =

| StdInChI = InChI=1S/C15H23N3O4S/c1-9(2)13(14(16)19)17-15(20)11-7-6-10(3)12(8-11)23(21,22)18(4)5/h6-9,13H,1-5H3,(H2,16,19)(H,17,20)/t13-/m0/s1

| StdInChI_comment =

| StdInChIKey = KYNAATZHNRULED-ZDUSSCGKSA-N

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

AB-MDMSBA is a novel synthetic compound that has been sold as a designer drug. It has been detected by drug checking services in Australia and New Zealand being misrepresented as a benzodiazepine.{{Cite web | title = Synthetic cannabinoid AB-MDMSBA found in 'benzodiazepine' samples - The Know | date = 2024-12-10 | url = https://theknow.org.au/alerts_warnings/synthetic-cannabinoid-ab-mdmsba-found-in-benzodiazepine-samples/ | access-date = 2025-06-10 | website = theknow.org.au | language = en }}{{Cite web | title = New synthetic cannabinoid misrepresented as a benzodiazepine | url = https://www.highalert.nz/alerts-and-notifications/new-synthetic-cannabinoid-misrepresented-as-a-benzodiazepine/ | access-date = 2025-06-10 | website = High Alert | language = en }}

It is structurally similar to other arylsulfonamide-based synthetic cannabinoids such as QMPSB.{{Cite journal | vauthors = Lebon F, Christophe B, Burton M, De Ryck M, Quéré L, Lambeng N | title = Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies | journal = Bioorganic & Medicinal Chemistry Letters | volume = 17 | issue = 1 | pages = 272–277 | date = January 2007 | pmid = 17027269 | doi = 10.1016/j.bmcl.2006.09.049 | url = https://linkinghub.elsevier.com/retrieve/pii/S0960894X06011061 | language = en }} This class of synthetic cannabinoid has previously been targeted toward greater selectivity of the cannabinoid receptor CB2 over CB1.{{Cite journal | vauthors = Ajello CW, Worm K, Bourdonnec BL, Savolainen MA, O'Hare H, Cassel JA, Stabley GJ, DeHaven RN, LaBuda CJ, Koblish M, Little PJ, Brogdon BL, Smith SA, Dolle RE, Goodman AJ | title = CB2 selective sulfamoyl benzamides: Optimization of the amide functionality | journal = Bioorganic & Medicinal Chemistry Letters | volume = 19 | issue = 2 | pages = 309–313 | date = January 2009 | pmid = 19091565 | doi = 10.1016/j.bmcl.2008.11.091 | url = https://linkinghub.elsevier.com/retrieve/pii/S0960894X08014765 | language = en }} The activity of AB-MDMSBA against either cannabinoid receptor is unknown.

References

{{Reflist}}